In 2024, several research and pharmacological advancements were made for tardive dyskinesia, a movement disorder caused by ...

A new study published in the Asian Journal of Psychiatry showed that people of Indian heritage require lower effective ...

Lyu X, Li Z, Chen S, et al. Transcranial direct current stimulation improves tardive dyskinesia in long-term hospitalized patients with chronic schizophrenia. Clin Neurophysiol. 2024;166:20-30. doi:10 ...

A 28-year-old Middle Eastern man develops severe motor disturbances, including muscle rigidity, tremors, a parkinsonian gait, and involuntary, jerky limb movements, following the administration of a 3 ...

(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) Monday said data from Phase 3 KINECT-3 and KINECT-4 studies showed that treatment with Ingrezza brought holistic improvements over time in patients with ...

US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 ...

SAN DIEGO - Neurocrine (NASDAQ:NBIX) Biosciences, Inc. (NASDAQ:NBIX) revealed study results indicating that nearly 60% of participants achieved remission of tardive dyskinesia after 48 weeks of ...

IMPACT-TD Registry, the largest study evaluating holistic effects of tardive dyskinesia (TD), highlights that there is a high burden of TD on quality of life regardless of a person’s underlying mental ...